Research and Markets: Dementia Global Clinical Trials Review, H2, 2012

<0> Research and Markets: Dementia Global Clinical Trials Review, H2, 2012 </0>

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of GlobalData's new report "Dementia Global Clinical Trials Review, H2, 2012" to their offering.

This report provides elemental information and data relating to the clinical trials on Dementia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dementia.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations

- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

- Listings of discontinued trials (suspended, withdrawn and terminated)

- Understand the dynamics of a particular indication in a condensed manner

- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

- Obtain discontinued trial listing for trials across the globe

- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Source: GlobalData

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.